Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The economic burden of dementia in Europe: COIN-Eu dementia.

Journal of Alzheimer's disease : JAD·2026
Same author

Neurosarcoidosis as an elusive mimicker of infection and neoplasia: a case report.

Journal of neurology·2026
Same author

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal of neurology·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Ultra-high-performance liquid chromatography high-resolution mass spectrometry-based screening of purine and pyrimidine metabolites in cow milk collected across 4 different seasons.

JDS communications·2026

Related Experiment Video

Updated: Aug 13, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Methods for Brain Atrophy MR Quantification in Multiple Sclerosis: Application to the Multicenter INNI Dataset.

Loredana Storelli1, Elisabetta Pagani1, Patrizia Pantano2,3

  • 1Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Journal of Magnetic Resonance Imaging : JMRI
|January 20, 2023
PubMed
Summary

This study compared brain atrophy measurement methods in multiple sclerosis (MS), finding Statistical Parametric Mapping (SPM) and Jim software showed the best agreement and effect sizes for gray matter atrophy.

Keywords:
Italian Neuroimaging Network Initiativeatrophy pipelinesbrain atrophymultiple sclerosis

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.1K
Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images
06:48

Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images

Published on: January 7, 2019

9.0K

Related Experiment Videos

Last Updated: Aug 13, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.1K
Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images
06:48

Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images

Published on: January 7, 2019

9.0K

Area of Science:

  • Neuroimaging
  • Neurology
  • Medical Image Analysis

Background:

  • Current multiple sclerosis (MS) therapies focus on neurodegeneration, but integrating atrophy measurements into clinical practice remains a challenge.
  • Accurate and reliable quantification of brain atrophy is crucial for monitoring MS progression and treatment efficacy.

Purpose of the Study:

  • To compare the performance of different software tools for measuring whole-brain and gray matter (GM) atrophy in MS patients.
  • To evaluate the consistency and accuracy of atrophy measurements using Structural Image Evaluation using Normalization of Atrophy (SIENA-X/XL), Statistical Parametric Mapping (SPM-v12), and Jim-v8.

Main Methods:

  • Utilized a retrospective dataset from the Italian Neuroimaging Network Initiative (INNI) including 466 MS patients and 279 healthy controls (HC).
  • Applied SIENA-X/XL, SPM-v12, and Jim-v8 to T1-weighted and T2-weighted MRI scans to assess cross-sectional and longitudinal brain atrophy.
  • Evaluated intraclass correlation coefficients (ICC), effect sizes (Cohen's d), and sample size requirements for atrophy progression.

Main Results:

  • SPM-v12 and Jim-v8 demonstrated significant agreement for both cross-sectional and longitudinal gray matter (GM) atrophy measurements.
  • SIENA-X/XL showed no significant agreement with SPM-v12 or Jim-v8 for whole-brain and GM volume comparisons.
  • SPM-v12 and Jim-v8 yielded the highest effect sizes for cross-sectional GM atrophy, while Jim-v8 and SIENA(XL) required the smallest sample sizes for atrophy progression detection.

Conclusions:

  • The choice of brain atrophy analysis pipeline is critical for MS research and clinical applications.
  • SPM-v12 and Jim-v8 are recommended for their robust performance in quantifying GM atrophy in MS.
  • Further consideration of these validated methods can improve the integration of atrophy measures into clinical MS management.